303 related articles for article (PubMed ID: 10862756)
1. FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts.
Kuang AA; Diehl GE; Zhang J; Winoto A
J Biol Chem; 2000 Aug; 275(33):25065-8. PubMed ID: 10862756
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines.
Shetty S; Gladden JB; Henson ES; Hu X; Villanueva J; Haney N; Gibson SB
Apoptosis; 2002 Oct; 7(5):413-20. PubMed ID: 12207174
[TBL] [Abstract][Full Text] [Related]
3. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
4. Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis.
Harper N; Hughes M; MacFarlane M; Cohen GM
J Biol Chem; 2003 Jul; 278(28):25534-41. PubMed ID: 12721308
[TBL] [Abstract][Full Text] [Related]
5. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
Suliman A; Lam A; Datta R; Srivastava RK
Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
[TBL] [Abstract][Full Text] [Related]
6. Molecular requirements for the combined effects of TRAIL and ionising radiation.
Marini P; Jendrossek V; Durand E; Gruber C; Budach W; Belka C
Radiother Oncol; 2003 Aug; 68(2):189-98. PubMed ID: 12972315
[TBL] [Abstract][Full Text] [Related]
7. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
[TBL] [Abstract][Full Text] [Related]
8. Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD.
Thomas LR; Henson A; Reed JC; Salsbury FR; Thorburn A
J Biol Chem; 2004 Jul; 279(31):32780-5. PubMed ID: 15173180
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus E1A reverses the resistance of normal primary human lung fibroblast cells to TRAIL through DR5 upregulation and caspase 8-dependent pathway.
Zhu H; Ling W; Hu B; Su Y; Qiu S; Xiao W; Qi Y
Cancer Biol Ther; 2006 Feb; 5(2):180-8. PubMed ID: 16357524
[TBL] [Abstract][Full Text] [Related]
10. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis.
Higuchi H; Bronk SF; Takikawa Y; Werneburg N; Takimoto R; El-Deiry W; Gores GJ
J Biol Chem; 2001 Oct; 276(42):38610-8. PubMed ID: 11507096
[TBL] [Abstract][Full Text] [Related]
11. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.
Kischkel FC; Lawrence DA; Chuntharapai A; Schow P; Kim KJ; Ashkenazi A
Immunity; 2000 Jun; 12(6):611-20. PubMed ID: 10894161
[TBL] [Abstract][Full Text] [Related]
12. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
[TBL] [Abstract][Full Text] [Related]
13. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.
Schneider P; Thome M; Burns K; Bodmer JL; Hofmann K; Kataoka T; Holler N; Tschopp J
Immunity; 1997 Dec; 7(6):831-6. PubMed ID: 9430228
[TBL] [Abstract][Full Text] [Related]
14. Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.
Bergeron S; Beauchemin M; Bertrand R
Mol Cancer Ther; 2004 Dec; 3(12):1659-69. PubMed ID: 15634660
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling.
Harper N; Hughes MA; Farrow SN; Cohen GM; MacFarlane M
J Biol Chem; 2003 Nov; 278(45):44338-47. PubMed ID: 12920112
[TBL] [Abstract][Full Text] [Related]
16. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
17. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation.
Thomas LR; Johnson RL; Reed JC; Thorburn A
J Biol Chem; 2004 Dec; 279(50):52479-86. PubMed ID: 15452120
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
Walczak H; Degli-Esposti MA; Johnson RS; Smolak PJ; Waugh JY; Boiani N; Timour MS; Gerhart MJ; Schooley KA; Smith CA; Goodwin RG; Rauch CT
EMBO J; 1997 Sep; 16(17):5386-97. PubMed ID: 9311998
[TBL] [Abstract][Full Text] [Related]
19. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
20. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
